The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

FC, Breedveld; MH, Weisman; AF, Kavanaugh; SB, Cohen; K, Pavelka; Vollenhoven R, van; J, Sharp; JL, Perez; GT, Spencer-Green

doi:10.1002/art.21519

Public

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Shared by NobleBlocks on Jan 1, 2006 • 12:00 AM UTC

Authors:

Breedveld FC

Weisman MH

Kavanaugh AF

Abstract

<h4>Objective</h4>To compare the efficacy and safety of adalimumab plus methotrexate (MTX) versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive rheumatoid arthritis (RA) who had not previously received MTX treatment.<h4>Methods</h4>This was a 2-year, multicenter, doubl...

Discussions